Biogen Inc. (BIIB) Cantor Fitzgerald Global Healthcare Conference (Transcript)
Express News | Biogen Exec Says if FDA's Review for Subcutaneous Leqembi Is Expedited Approval Could Come After 8 Months From Submission Vs 12 Months
Express News | Biogen Exec Says Co Expects Immunogenicity Data to Be Ready by October to Submit to FDA for Subcutaneous Leqembi Filing - Cantor Fitzgerald Conference
Express News | Biogen Canada: Regulatory Decision on New Drug Submission for Omaveloxolone Is Anticipated in Early 2025
Biogen's New Drug Submission for Omaveloxolone Accepted for Priority Review by Health Canada for the Treatment of Friedreich's Ataxia
Here's Why Biogen Inc. (BIIB) Is a Strong Value Stock